Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression

被引:7
|
作者
Domowicz, Miriam S. [1 ]
Chan, Wen-Ching [2 ]
Claudio-Vazquez, Patricia [1 ]
Gonzalez, Tatiana [1 ]
Schwartz, Nancy B. [1 ,3 ]
机构
[1] Univ Chicago, Med Ctr, Dept Pediat, Biol Sci Div, 5841 S Maryland Ave,MC 5058, Chicago, IL 60637 USA
[2] Univ Chicago, Ctr Res Informat, Biol Sci Div, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Biochem & Mol Biol, Biol Sci Div, Chicago, IL 60637 USA
关键词
Neuronal ceroid lipofuscinoses; Transcriptome; Lysosomal tripeptidyl peptidase 1; Pediatric neurodegeneration; Neuroinflammation; Choroid plexus; NEURONAL CEROID-LIPOFUSCINOSIS; TRIPEPTIDYL-PEPTIDASE-I; MATRIX METALLOPROTEINASE-12; CEREBROSPINAL-FLUID; GENE; CELLS; NEUROINFLAMMATION; PATHOLOGY; EXPRESSION; PROTEINS;
D O I
10.1186/s12974-021-02302-z
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Neuronal ceroid lipofuscinoses, (NCLs or Batten disease) are a group of inherited, early onset, fatal neurodegenerative diseases associated with mutations in 13 genes. All forms of the disease are characterized by lysosomal accumulation of fluorescent storage material, as well as profound neurodegeneration, but the relationship of the various genes' function to a single biological process is not obvious. In this study, we used a well-characterized mouse model of classical late infantile NCL (cLINCL) in which the tripeptidyl peptidase 1 (Tpp1) gene is disrupted by gene targeting, resulting in loss of detectable TPP1 activity and leading to progressive neurological phenotypes including ataxia, increased motor deficiency, and early death. Methods In order to identify genes and pathways that may contribute to progression of the neurodegenerative process, we analyzed forebrain/midbrain and cerebellar transcriptional differences at 1, 2, 3 and 4 months of age in control and TPP1-deficient mice by global RNA-sequencing. Results Progressive neurodegenerative inflammatory responses involving microglia, astrocytes and endothelial cells were observed, accompanied by activation of leukocyte extravasation signals and upregulation of nitric oxide production and reactive oxygen species. Several astrocytic (i.e., Gfap, C4b, Osmr, Serpina3n) and microglial (i.e., Ctss, Itgb2, Itgax, Lyz2) genes were identified as strong markers for assessing disease progression as they showed increased levels of expression in vivo over time. Furthermore, transient increased expression of choroid plexus genes was observed at 2 months in the lateral and fourth ventricle, highlighting an early role for the choroid plexus and cerebrospinal fluid in the disease pathology. Based on these gene expression changes, we concluded that neuroinflammation starts, for the most part, after 2 months in the Tpp1(-/-) brain and that activation of microglia and astrocytes occur more rapidly in cerebellum than in the rest of the brain; confirming increased severity of inflammation in this region. Conclusions These findings have led to a better understanding of cLINCL pathological onset and progression, which may aid in development of future therapeutic treatments for this disease.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression
    Miriam S. Domowicz
    Wen-Ching Chan
    Patricia Claudio-Vázquez
    Tatiana Gonzalez
    Nancy B. Schwartz
    Journal of Neuroinflammation, 18
  • [2] Monitoring Neuropsychological Function in CLN2 Disease
    Augustine, E.
    Adams, H.
    Baron, I. S.
    Bjoraker, K.
    Cohen-Pfeffer, J.
    Delaney, K.
    Elmerskog, B.
    Newsom-Davis, I
    Nickel, G.
    Rust, S.
    Shapiro, E.
    Tossebro, A. G.
    Schulz, A.
    ANNALS OF NEUROLOGY, 2018, 84 : S401 - S402
  • [3] A tailored mouse model of CLN2 disease: A nonsense mutant for testing personalized therapies
    Geraets, Ryan D.
    Langin, Logan M.
    Cain, Jacob T.
    Parker, Camille M.
    Beraldi, Rosanna
    Kovacs, Attila D.
    Weimer, Jill M.
    Pearce, David A.
    PLOS ONE, 2017, 12 (05):
  • [4] Management Strategies for CLN2 Disease
    Williams, Ruth E.
    Adams, Heather R.
    Blohm, Martin
    Cohen-Pfeffer, Jessica L.
    de los Reyes, Emily
    Denecke, Jonas
    Drago, Kristen
    Fairhurst, Charlie
    Frazier, Margie
    Guelbert, Norberto
    Kiss, Szilard
    Kofler, Annamaria
    Lawson, John A.
    Lehwald, Lenora
    Leung, Mary-Anne
    Mikhaylova, Svetlana
    Mink, Jonathan W.
    Nickel, Miriam
    Shediac, Renee
    Sims, Katherine
    Specchio, Nicola
    Topcu, Meral
    von Loebbecke, Ina
    West, Andrea
    Zernikow, Boris
    Schulz, Angela
    PEDIATRIC NEUROLOGY, 2017, 69 : 102 - 112
  • [5] Brain Region-Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
    Dyke, J. P.
    Sondhi, D.
    Voss, H. U.
    Yohay, K.
    Hollmann, C.
    Mancenido, D.
    Kaminsky, S. M.
    Heier, L. A.
    Rudser, K. D.
    Kosofsky, B.
    Casey, B. J.
    Crystal, R. G.
    Balton, D.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2016, 37 (06) : 1160 - 1169
  • [6] Magnetic resonance brain volumetry biomarkers of CLN2 Batten disease identified with miniswine model
    Knoernschild, Kevin
    Johnson, Hans J.
    Schroeder, Kimberly E.
    Swier, Vicki J.
    White, Katherine A.
    Sato, Takashi S.
    Rogers, Christopher S.
    Weimer, Jill M.
    Sieren, Jessica C.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [7] Magnetic resonance brain volumetry biomarkers of CLN2 Batten disease identified with miniswine model
    Kevin Knoernschild
    Hans J. Johnson
    Kimberly E. Schroeder
    Vicki J. Swier
    Katherine A. White
    Takashi S. Sato
    Christopher S. Rogers
    Jill M. Weimer
    Jessica C. Sieren
    Scientific Reports, 13
  • [8] Loss of visual function associated with photoreceptor degeneration in CLN2 disease
    Ohnsman, Christina
    Huang, Wei Chieh
    Atiskova, Yevgeniya
    Wildner, Jan
    Falabella, Paulo
    Schulz, Angela
    Dulz, Simon
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 95 - 95
  • [9] Expert opinion on the management of CLN2 disease
    Schulz, Angela
    Adams, Heather R.
    Blohm, Martin
    Cohen-Pfeffer, Jessica L.
    de los Reyes, Emily
    Denecke, Jonas
    Drago, Kristen
    Fairhurst, Charlie
    Frazier, Margie
    Guelbert, Norberto
    Kiss, Szilard
    Kofler, Annamaria
    Lawson, John
    Lehwald, Lenora
    Leung, Mary-Anne
    Mikhailova, Svetlana
    Mink, Jonathan W.
    Nickel, Miriam
    Shediac, Renee
    Sims, Katherine
    Specchio, Nicola
    Topcu, Meral
    von Loebbecke, Ina
    West, Andrea
    Williams, Ruth E.
    MOLECULAR GENETICS AND METABOLISM, 2016, 117 (02) : S103 - S104
  • [10] Retinal degeneration in patients with CLN2 disease
    Dulz, Simon
    Schwering, Christoph
    Wibbeler, Eva
    Nickel, Miriam
    Spitzer, Martin
    Schulz, Angela
    Atiskova, Yevgeniya
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)